ABN.AS: $40.75 ▲ 0.30 (0.74%)DSFIR.AS: $99.66 ▼ -0.99 (-0.98%)GMAB.CO: $2,487.00 ▲ 42.00 (1.72%)REP.MC: $29.21 ▼ -0.31 (-1.05%)SOON.SW: $267.80 ▲ 3.20 (1.21%)CRWD: $263.07 ▼ -11.97 (-4.35%)HPE: $70.13 ▼ -3.33 (-4.53%)AMD: $590.04 ▼ -18.06 (-2.97%)DELL: $574.99 ▼ -11.07 (-1.89%)PANW: $399.75 ▼ -19.03 (-4.54%)MRNA: $214.23 ▼ -10.77 (-4.79%)AAPL: $339.52 ▲ 2.88 (0.86%)AMZN: $259.82 ▼ -2.61 (-0.99%)MSFT: $539.81 ▲ 4.74 (0.89%)NVDA: $226.42 ▼ -2.86 (-1.25%)CIEN: $403.29 ▼ -46.48 (-10.34%)DDOG: $287.72 ▼ -5.54 (-1.89%)SNPS: $503.07 ▼ -6.92 (-1.36%)CAP.PA: $115.35 ▲ 0.30 (0.26%)TSCO.L: $511.00 ▲ 7.20 (1.43%)WKL.AS: $77.16 ▲ 2.16 (2.88%)

Company Details

GRAIL, Inc.

GRAL - NASDAQ

Identifiants & Marche

Ticker GRAL
ISIN US3847471014
CIK 0001699031
Bourse NASDAQ
Devise USD

Classification

Secteur Healthcare

Entreprise

Pays US
Siege N/A
Fondee N/A
Site Web Lien

Description

GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.